DexCom, Inc. (NASDAQ:DXCM) Position Raised by Natixis Advisors LLC

Natixis Advisors LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 446.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 193,532 shares of the medical device company's stock after purchasing an additional 158,124 shares during the period. Natixis Advisors LLC's holdings in DexCom were worth $15,051,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd purchased a new stake in shares of DexCom in the fourth quarter valued at $793,000. Intact Investment Management Inc. raised its stake in DexCom by 23.7% in the 4th quarter. Intact Investment Management Inc. now owns 12,000 shares of the medical device company's stock valued at $933,000 after purchasing an additional 2,300 shares during the last quarter. LBP AM SA lifted its holdings in DexCom by 5.0% in the 4th quarter. LBP AM SA now owns 215,810 shares of the medical device company's stock valued at $16,784,000 after purchasing an additional 10,320 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in shares of DexCom by 3.5% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 283,654 shares of the medical device company's stock worth $22,114,000 after purchasing an additional 9,668 shares during the last quarter. Finally, Vestcor Inc boosted its stake in shares of DexCom by 26.2% during the 4th quarter. Vestcor Inc now owns 15,832 shares of the medical device company's stock worth $1,231,000 after purchasing an additional 3,291 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Remove Ads

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by insiders.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $1.31 during trading on Friday, reaching $73.80. 5,560,851 shares of the company's stock traded hands, compared to its average volume of 3,912,424. The stock has a market capitalization of $28.84 billion, a P/E ratio of 51.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50 day moving average of $83.33 and a 200-day moving average of $76.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the topic of several recent analyst reports. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.